Witnessing the stock’s movement on the chart, on February 19, 2021, Genocea Biosciences Inc. (NASDAQ: GNCA) set off with pace as it heaved 6.80% to $3.61. During the day, the stock rose to $3.92 and sunk to $3.40 before settling in for the price of $3.38 at the close. Taking a more long-term approach, GNCA posted a 52-week range of $1.10-$5.75.
Meanwhile, its Annual Earning per share during the time was 36.40%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 30.00%. This publicly-traded company’s shares outstanding now amounts to $55.49 million, simultaneously with a float of $48.03 million. The organization now has a market capitalization sitting at $174.51 million. At the time of writing, stock’s 50-day Moving Average stood at $2.80, while the 200-day Moving Average is $2.56.
It is quite fundamental to gauge the extent of the productivity of the business which is accounted for 59 workers. For the Profitability, stocks operating margin was -3457.62 and Pretax Margin of -3216.63.
Genocea Biosciences Inc. (GNCA) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Genocea Biosciences Inc.’s current insider ownership accounts for 6.98%, in contrast to 56.40% institutional ownership. According to the most recent insider trade that took place on Nov 10, this organization’s President and CEO bought 4,760 shares at the rate of 2.06, making the entire transaction reach 9,806 in total value, affecting insider ownership by 4,760. Preceding that transaction, on Jul 24, Company’s 10% Owner bought 3,151,260 for 2.25, making the whole transaction’s value amount to 7,090,335. This particular insider is now the holder of 10,376,936 in total.
Genocea Biosciences Inc. (GNCA) Earnings and Revenue Records
As on 12/30/2020, Multinational firm has announced its last quarter scores, in which it reported -$0.23 earnings per share (EPS) for the period falling under the consensus outlook (set at -$0.21) by -$0.02. This company achieved a net margin of -3216.63 while generating a return on equity of -256.96. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
Genocea Biosciences Inc.’s EPS increase for this current 12-month fiscal period is 30.00% and is forecasted to reach -0.73 in the upcoming year.
Genocea Biosciences Inc. (NASDAQ: GNCA) Trading Performance Indicators
Let’s observe the current performance indicators for Genocea Biosciences Inc. (GNCA). It’s Quick Ratio in the last reported quarter now stands at 3.80. The Stock has managed to achieve an average true range (ATR) of 0.39. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 124.65.
In the same vein, GNCA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.16, a figure that is expected to reach -0.19 in the next quarter, and analysts are predicting that it will be -0.73 at the market close of one year from today.
Technical Analysis of Genocea Biosciences Inc. (GNCA)
Going through the that latest performance of [Genocea Biosciences Inc., GNCA]. Its last 5-days volume of 0.92 million indicated improvement to the volume of 0.78 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 49.98% While, its Average True Range was 0.40.
Raw Stochastic average of Genocea Biosciences Inc. (GNCA) in the period of the previous 100 days is set at 80.62%, which indicates a major rise in contrast to 63.60% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 114.34% that was higher than 97.98% volatility it exhibited in the past 100-days period.